Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

被引:11
|
作者
Choi, Soojeong [1 ]
Lee, Young Jae [2 ]
Jeong, Jae Ho [3 ]
Jung, Jinhong [4 ]
Lee, Jong Won [1 ]
Kim, Hee Jeong [1 ]
Ko, Beom Seok [1 ]
Son, Byung Ho [1 ]
Ahn, Sei Hyun [1 ]
Lee, Yura [1 ,5 ]
Chung, Il Yong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Obstet & Gynecol, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Informat, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
breast neoplasms; dilatation and curettage; gynecological examination; tamoxifen; endometrial neoplasms; SURGICAL ADJUVANT BREAST; ENDOCRINE THERAPY; LONG-TERM; WOMEN; PREVENTION; SOCIETY;
D O I
10.3389/fonc.2021.636378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea. Methods A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan-Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model. Results Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person-years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged >= 60 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185-11.613], 50-59 years (HR, 4.343; 95% CI, 2.122-8.891), and 40-49 years (HR, 2.121; 95% CI, 1.068-4.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person-years (PY); HR, 12.460; 95% CI, 2.698-57.522] and aged 40-49 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966-18.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more. Conclusion Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors
    Chlebowski, Rowan T.
    Schottinger, Joanne E.
    Shi, Jiaxiao
    Chung, Joanie
    Haque, Reina
    CANCER, 2015, 121 (13) : 2147 - 2155
  • [2] Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors
    Sestak, Ivana
    Cuzick, Jack
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (05) : 425 - 432
  • [3] Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
    Lee, Maria
    Piao, Jinlan
    Jeon, Myung Jae
    YONSEI MEDICAL JOURNAL, 2020, 61 (04) : 317 - 322
  • [4] Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients
    AlZaabi, Adhari
    AlAmri, Hafsa
    ALAjmi, Ghadeer
    Allawati, Manhal
    Muhanna, Fatema
    Alabri, Ruqaia
    AlBusaidi, Fatema
    AlGhafri, Shaima
    Al-Mirza, Abdulrahman A.
    Al Baimani, Khalid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [5] Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast Cancer
    Koji Yamazawa
    Yukimasa Miyazawa
    Masato Suzuki
    Maki Wakabayashi
    Hiroshi Kaku
    Hideo Matsui
    Souei Sekiya
    Surgery Today, 2006, 36 : 41 - 46
  • [6] Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer
    Yamazawa, K
    Miyazawa, Y
    Suzuki, M
    Wakabayashi, M
    Kaku, H
    Matsui, H
    Sekiya, S
    SURGERY TODAY, 2006, 36 (01) : 41 - 46
  • [7] Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer - Comparison of cohorts treated with and without tamoxifen
    Saadat, Mandana
    Truong, Pauline T.
    Kader, Hosam A.
    Speers, Caroline H.
    Berthelet, Eric
    McMurtrie, Elissa
    Olivotto, Ivo A.
    CANCER, 2007, 110 (01) : 31 - 37
  • [8] Endometrial Cytologic Findings In Tamoxifen-Treated Breast Cancer Patients
    Hachisuga, Toru
    Emoto, Makoto
    Kawarabayashi, Tatsuhiko
    Kamihana, Yutaka
    Nabeshima, Kazuki
    ACTA CYTOLOGICA, 2009, 53 (01) : 24 - 28
  • [9] Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen
    Salazar, EL
    Paredes, A
    Calzada, L
    GYNECOLOGICAL ENDOCRINOLOGY, 2005, 21 (06) : 312 - 316
  • [10] Is screening for endometrial cancer necessary in asymptomatic women treated with tamoxifen for breast cancer?
    Ju, U. Chul
    Kang, Woo Dae
    Kim, Seok Mo
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (02) : 169 - 174